Healthcare Industry Veteran O’Grady to Head
Growth Organization
Amwell®, (NYSE: AMWL) a national telehealth leader, today
announced the appointment of Brendan O’Grady to the position of
Chief Commercial & Growth Officer, effective immediately. Mr.
O’Grady will report to Amwell’s Chairman and Co-CEO Ido
Schoenberg.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210722005157/en/
Brendan O'Grady (Photo: Business
Wire)
“Brendan has been a meaningful contributor to Amwell’s strategy
and growth since joining our Board in 2015,” said Ido Schoenberg,
Chairman and Co-CEO. “His long and impressive track record
successfully leading large scale growth in sizable healthcare
organizations fits well with our plans. Having had the benefit of
seeing his impact as a Board member, we are confident he
understands our company, mission, and the tremendous opportunity
ahead.”
In his new role, Mr. O’Grady will be responsible for driving
strategic growth initiatives and leading the business development,
sales and commercial enablement, marketing, channel partner, and
account management teams. He will support the expansion of Amwell’s
strategy across geographies and new markets, as well as identify
new pathways for growth.
Mr. O’Grady joins the Company with over 30 years of experience
in the healthcare sector, bringing a successful track record of
growing and scaling large organizations. Much of his career has
concentrated on creating and implementing innovative solutions and
teams to drive organizational growth and to advance healthcare
access through medicine. In his most recent role, Mr. O’Grady
served as President and CEO of Teva Pharmaceuticals’ North America
Business, where he was responsible for managing and scaling the
productivity, profitability, and overall growth of all Teva’s North
American business operations.
Mr. O’Grady commented, “Amwell has done an incredible job
growing into one of healthcare’s most distinct, impactful
companies, sitting at the center of care delivery. I am excited to
join Ido, Roy and the team full-time with an eye on growing the
company’s presence in familiar ways and exploring the unique
opportunity that comes with the company’s deep connections to all
the major players in healthcare, from providers, to insurers,
employers and innovators.”
Prior to his role as President and CEO of Teva Pharmaceuticals’
North America business, Mr. O’Grady served as Chief Commercial
Officer for Teva Pharmaceutical’s Global Specialty Medicine
division and the interim head of Teva’s European Specialty
business. Mr. O’Grady also held the positions of President &
CEO of North America Generic Medicines and Senior Vice President
and Head of US Market Access & Patient Services for Teva’s U.S.
specialty business. Prior to joining Teva, O’Grady spent 10 years
with Sanofi predecessor companies in a variety of commercial and
medical affairs roles. In addition to serving on Amwell’s board
since 2015, Mr. O’Grady has served as a board member for the
Association of Accessible Medicines and most recently as a board
member of the Pharmaceutical Research Manufacturers of America
(commonly known as PhRMA).
About Amwell
Amwell is a leading telehealth platform in the United States and
globally, connecting and enabling providers, insurers, patients,
and innovators to deliver greater access to more affordable, higher
quality care. Amwell believes that digital care delivery will
transform healthcare. The Company offers a single, comprehensive
platform to support all telehealth needs from urgent to acute and
post-acute care, as well as chronic care management and healthy
living. With over a decade of experience, Amwell powers telehealth
solutions for over 2,000 hospitals and 55 health plan partners with
over 36,000 employers, covering over 80 million lives. For more
information, please visit https://business.amwell.com/.
American Well, Amwell, Converge and Carepoint are registered
trademarks or trademarks of American Well Corporation in the United
States and other countries. All other trademarks used herein are
the property of their respective owners.
Forward-Looking Statements
This press release contains forward-looking statements about us
and our industry that involve substantial risks and uncertainties
and are based on our beliefs and assumptions and on information
currently available to us. All statements other than statements of
historical facts contained in this press release, including
statements regarding our future results of operations, financial
condition, business strategy and plans and objectives of management
for future operations, are forward-looking statements. In some
cases, you can identify forward-looking statements because they
contain words such as “anticipate,” “believe,” “could,” “estimate,”
“expect,” “intend,” “may,” “plan,” “potential,” “predict,”
“project,” “should,” “will,” or “would,” or the negative of these
words or other similar terms or expressions.
Forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause our actual results,
performance, or achievements to be materially different from any
future results, performance or achievements expressed or implied by
the forward-looking statements. Forward-looking statements
represent our beliefs and assumptions only as of the date of this
release. These statements, and related risks, uncertainties,
factors and assumptions, include, but are not limited to: weak
growth and increased volatility in the telehealth market; inability
to adapt to rapid technological changes; increased competition from
existing and potential new participants in the healthcare industry;
changes in healthcare laws, regulations or trends and our ability
to operate in the heavily regulated healthcare industry; our
ability to comply with federal and state privacy regulations; the
significant liability that could result from a cybersecurity
breach; and other factors described under ‘Risk Factors’ in our
Form 10-K filed with the SEC on March 26, 2021. These risks are not
exhaustive. Except as required by law, we assume no obligation to
update these forward-looking statements, or to update the reasons
actual results could differ materially from those anticipated in
the forward-looking statements, even if new information becomes
available in the future. Further information on factors that could
cause actual results to differ materially from the results
anticipated by our forward-looking statements is included in the
reports we have filed or will file with the Securities and Exchange
Commission. These filings, when available, are available on the
investor relations section of our website at investors.amwell.com
and on the SEC’s website at www.sec.gov.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210722005157/en/
Holly Spring Press@amwell.com 781-888-8219
American Well (NYSE:AMWL)
Historical Stock Chart
From Mar 2024 to Apr 2024
American Well (NYSE:AMWL)
Historical Stock Chart
From Apr 2023 to Apr 2024